Ibogaine Deaths: What the Published Record Shows

Every article about ibogaine safety eventually reaches for a number, and almost all of them reach for the same one. Nineteen. It appears in news reports, in clinic disclosures, in policy submissions and in the summary Google shows above its own search results.

The number is real. It is also the answer to a narrower question than the one people are asking when they type it, and it stopped being current eighteen years ago.

Where the number comes from

In 2012, a psychiatrist, a forensic toxicologist and a medical examiner published a systematic review in the Journal of Forensic Sciences. They collected all available autopsy, toxicological and investigative reports for every known death outside West Central Africa temporally related to ibogaine between 1990 and 2008, and found nineteen people: fifteen men and four women, aged 24 to 54.

Read the qualifiers, because they carry the meaning.

Outside West Central Africa. Ritual use in Gabon and neighbouring countries is outside the series. No comparable forensic record exists for it, so its absence here says nothing in either direction.

Temporally related. The review counted deaths that happened close enough in time to the dose to be worth investigating. That is deliberately weaker than “caused by”, and the authors are explicit about it.

Through 2008. The series closes eighteen years before this page was written.

The count before it, and the count after it

Nineteen is one figure in a sequence, and the sequence is more informative than any single entry.

The temptation is to subtract, and it should be resisted. The 2018 figure counts worldwide and the 2012 figure counts outside West Central Africa. They do not share a geography, a period or an evidentiary standard, so the difference between them is not a number of new deaths. What the sequence does establish is that the total was still rising when anyone last looked, and that the last look was eight years ago.

The reviews published since have not tried to recount. A systematic review of adverse events between 2015 and 2020 found eighteen studies and catalogued what went wrong in them, with cardiac effects the most common category and QTc prolongation the most common cardiac effect. It made no attempt at a fatality total, and it closed by calling for phase I trials that would establish the safety of a known dose of a standardised product, which reads as an acknowledgement that neither is currently available.

What the deaths had in common

The most useful finding in the 2012 review is not the number. It is the negative result underneath it.

The authors looked for a characteristic syndrome of neurotoxicity, the signature a drug leaves when it poisons nervous tissue directly. The evidence did not suggest one. On that evidence, a general toxic effect on the brain is not what the autopsies point to.

What they found instead was context. In 12 of the 14 cases where postmortem data were adequate, advanced pre-existing medical conditions, mainly cardiovascular, or one or more commonly abused substances explained or contributed to the death. The review named two further risk factors: seizures associated with withdrawal from alcohol and benzodiazepines, and the uninformed use of raw ethnopharmacological preparations rather than the isolated alkaloid.

This is the part that changes what a reader should do with the page. The question stops being how dangerous the drug is in the abstract, and becomes what is already true of a particular heart, and what else is in a particular body. Both are measurable before the fact. Cardiac screening is the whole argument, and it rests on this paragraph rather than on the count.

The timing carries its own warning. Deaths occurred between 1.5 and 76 hours after the dose. Seventy-six hours is more than three days, long after the visionary phase has ended and long after most people would consider the event over. The mechanism explains why: noribogaine, the metabolite, persists far beyond the experience, and the electrical vulnerability persists with it.

Iboga deaths and ibogaine deaths are not the same category

Most of this page uses the two words as though they were interchangeable. They are not, and the fatality record is one of the places where the difference has consequences.

Ibogaine is a single alkaloid. Iboga is a plant, and its root bark contains ibogaine alongside a dozen other alkaloids in proportions that vary with the plant, the part used and the preparation. A death after purified ibogaine hydrochloride and a death after a spoonful of root bark are not the same event, and the 2012 review singled out the uninformed use of raw ethnopharmacological preparations as a risk factor in its own right.

The clearest documented example is a case published in the Journal of Forensic Sciences in 2013. A 27-year-old man died twelve hours after ingesting powdered iboga root taken in the context of withdrawal treatment. What makes the case unusually informative is that the investigators measured the powder as well as the body: the powder’s iboga content was measured at 7.2%. They also found methadone and diazepam at therapeutic concentrations, and attributed the death to a substantial quantity of iboga taken alongside both.

Three things in that paragraph are worth separating.

The alkaloid content was measured after the death, not before it, and 7.2% is a figure nobody could have known in advance. Somebody weighing out a plant powder is not measuring a dose in any sense the word usually carries, which is the same problem the dosage page runs into from the other direction.

The methadone matters as much as the iboga. Leaving an opioid agonist for ibogaine is the combination that recurs in these reports, and drug interactions covers why.

And the label on a plant powder is not evidence of what is inside it. The most extreme documented case on this site is a powder sold as iboga that contained no iboga at all, which is the failure mode the word iboga hides that the word ibogaine does not.

Why monitoring does not settle it

The most common response to the fatality record is that those deaths happened without proper medical supervision. It is a reasonable thought and the evidence does not fully support it.

The clearest test comes from watching people forward from the dose rather than reconstructing afterwards. In an open-label observational study of fourteen patients with opioid use disorder, run in a university medical centre psychiatry department in the Netherlands and published in Addiction, participants were converted from opioid maintenance to oral morphine beforehand, given a single 10 mg/kg dose, and monitored at intervals for at least 24 hours. Their potassium, calcium and magnesium were confirmed to be within normal ranges before dosing. This is closer to best practice than most of what happens in the field.

The maximum QT prolongation, corrected for heart rate, averaged 95 milliseconds, with a range from 29 to 146. Half the participants crossed 500 milliseconds, the threshold above which the risk of a dangerous arrhythmia is considered clinically serious. In six of the fourteen, the interval was still above 450 milliseconds more than 24 hours after the dose. Every patient developed transient ataxia severe enough that they could not walk without support.

No torsade de pointes occurred, but eight of the fourteen received a rescue magnesium infusion for QT prolongation, and the authors also record bradycardia and a fall in blood pressure. They describe the QTc prolongation as clinically relevant but reversible. Both halves of that phrase are load bearing. Screening did not prevent the electrical change. Monitoring caught it, and treatment on the ward contained it, in fourteen people.

There is no death rate

A count of deaths is not a risk. To turn nineteen, or 33, into a probability you would need to know how many people took ibogaine over the same period, and nobody does.

The scale of the gap is worth stating precisely. A systematic review of the clinical literature to December 2020 screened 743 records and found 24 studies covering 705 individuals who received ibogaine or noribogaine. Two fatalities are described within those 24 studies. That is the entire denominator the clinical literature supplies: roughly seven hundred people, in every study of any design published up to the end of 2020.

The number actually treated is far larger and entirely unrecorded. Most administration happens in private clinics that publish nothing, in countries with no registry, or outside any medical setting whatsoever. There is no mechanism by which anyone would learn the total, and there is no plan to build one.

So the honest position is uncomfortable in both directions. The count of deaths is certainly incomplete, because deaths outside a forensic system do not enter the literature. The rate could be low or high, and the published record cannot distinguish between those two possibilities. A page that tells you ibogaine is statistically safer than something else is inventing the arithmetic.

What we could not establish

Several things a reader might reasonably want are not available.

A current total. No systematic count has been published since 2018. We could not establish one ourselves, and we are not going to estimate a figure of this kind.

A breakdown by setting. Whether a death happened in a clinic with monitoring, in a clinic without it, or at home is recorded inconsistently in the source reports and is not tabulated in any of the reviews. The single most useful question about these deaths cannot be answered from the published record.

Deaths in West Central Africa. Ritual use has never been surveyed for mortality with anything comparable to the forensic review of Western cases. The absence of a figure is not evidence of an absence of deaths.

Non-fatal harm. People who survive with a permanent injury, cardiac or neurological, are not counted anywhere at all.

What follows from this

The fatality record does not answer the question most readers arrive with. It answers a different one, and answers it well: the harm runs through the heart, it runs through it for days rather than hours, and it concentrates in people who were already ill or already carrying other drugs.

That is a description of who is at risk rather than a probability that anyone is. The pages on contraindications, drug interactions and what screening should cover work through it in detail. Ibogaine side effects separates what is expected from what is dangerous, and what emergency preparedness should look like covers what has to be in the room for the hours this page is about. Buying iboga online covers the version of this with none of the screening at all, and it is where the uninformed use of raw preparations that the 2012 review named as a risk factor most often begins.